Research Shows the Growth of Legal Cannabis Sales

NEW YORK, February 8, 2018 /PRNewswire/ --

According to data published by Ameri Research Inc. the global legal marijuana market was valued at $14.3 billion in 2016 and is forecast to grow at a CAGR of 21.1% between 2017 and 2024, culminating in 2024 global sales of $63.5 billion. The legal cannabis market is witnessing healthy growth due to the increasing legalization and decriminalization of cannabis products across North America and Europe. The report also indicates that due to the complex regulatory structure at state level and federal level, the full potential of the market is not yet realized. On January 1st the state of California has joined the short list of states where sales of recreational cannabis are legal. Global Payout, Inc. (OTC: GOHE), GB Sciences, Inc. (OTC: GBLX), mCig, Inc. (OTC: MCIG), Abattis Bioceuticals Corp. (OTC: ATTBF), Vitality Biopharma, Inc. (OTC: VBIO)

The potential financial benefits from the legalization are important economically and politicly. Fortune reported that, "in order to collect $1 billion a year in taxes, the state will need to reach a projected $7 billion in annual legal recreational cannabis sales. At that rate, California would easily be the country's largest legal marijuana market, as the entire legal cannabis industry in the U.S. is expected to pull in roughly $10 billion in total sales for 2017. That number would almost certainly get a boost in the coming years, as legal markets grow in California and other states, such as Nevada and Massachusetts."

Global Payout, Inc. (OTC: GOHE) earlier this week announced breaking news that, "its majority owned subsidiary, MoneyTrac Technology, Inc. ("MTRAC", the "Company"), has executed a Sales Partnership and Commission Agreement with (""), an award winning and leading retail technology company that operates a cannabis media network, the Eyechronic network, that has already successfully partnered with almost 300 medical and retail dispensaries throughout the U.S. Through this agreement, MTRAC will effectively incorporate's retail technology products and "in-store media" services to reach customers of the multibillion dollar cannabis industry. This technology has been developed to empower the advertisement and customer engagement opportunities for dispensaries through the Eyechronic network. The network allows dispensaries to display product and promotional information, cross-promotional advertisements, and engaging and education-related information on digital screens installed and maintained by

With the vast network of dispensaries MTRAC has developed through the success of its PotSaver publication, the Company intends for its initial sales efforts of the Eyechronic network to be focused within the state of California, which currently boasts the fastest growing retail cannabis market in the U.S. Said MTRAC CEO, Vanessa Luna: "Establishing this sales partnership with is an incredibly effective way to deliver more value to the solutions and services we are providing to cannabis-related businesses. The team are true pioneers in the digital marketing and advertisement space and have established themselves as the premier provider of these services throughout the cannabis industry. I am pleased they recognize the value we can bring to their brand through the network of dispensaries we have created through our PotSaver publication, as well as through the invaluable expertise our team offers in developing and implementing successful sales and marketing strategies. I am extremely confident that this will be a partnership that is mutually beneficial to the objectives of each of our companies."

Said VP of Strategic Growth, Colby McKenzie: "Ms. Luna and the MoneyTrac team have done an impressive job over the past several months in establishing a valuable network of dispensaries in the state of California and other western regions. This agreement not only gives us the opportunity to tap into these relationships for the expansion of the Eyechronic network, but gives us a very unique and powerful opportunity to partner with a company that is quickly becoming one of the most prominent resources for dispensaries and other cannabis-related businesses in this industry." MTRAC fully intends to leverage the incorporation of the Eyechronic network into its suite of services and solutions towards the further expansion of its PotSaver brand in California and other west coast communities, in addition to increasing the overall value the publication will deliver to dispensaries."

GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. Recently, the company has filed a nonprovisional patent application to protect its cannabinoid-containing complex mixtures for the treatment of inflammatory disorders. The new patent application claims the benefit of GB Sciences' provisional patent previously filed on February 1, 2017; plus, additional data describing their mechanism of action and further supporting their claims. Inflammatory disorders, such as arthritis, asthma, eczema, psoriasis, Crohn's disease and Inflammatory Bowel Disease, represent a serious health burden in the US with over $200 billion spent annually. New cannabis-based therapies could significantly help both patients and society.  

mCig, Inc. (OTCQB: MCIG) is a diversified company servicing the legal cannabis, hemp and CBD markets. On January 29, 2018, the company has announced plans to launch an innovatively advanced hemp CBD-based formula for pets. Doctor of Bioengineering and Cardiology at Mt. Sinai Medical Center, Arkady Uryash, will be leading this new initiative in the rapidly expanding sixty-billion-dollar CBD pet industry market. The decision to expand into the pet products industry was based on extensive research conducted on customer and supplier inquiries. Comparison of research on how cannabinoids (including CBD) affects the human and animal body has shown that their effects share close similarities in interaction with endocannabinoid system (ECS).  Dogs and Cats were specifically found to share up to 70% biological homology with humans. Highly promising scientific conclusions indicate that CBD interacts in a similar way in canines and felines as it does in humans. Specifically, cannabinoid binding to ECS receptors within the dog and cat body can provide a longer lasting therapeutic effect without a risk of toxicity.

Abattis Bioceuticals Corp. (OTCQB: ATTBF) is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. On January 22, 2018, the company announced the formation of a new partnership with Faculty Brewing Co., a Vancouver-based craft brewery, to develop a hemp-infused, cannabinoid-rich, THC-free craft beer. Pursuant to a research services agreement between Abattis and Faculty Brewing, Abattis will conduct research and development activities related to the development of a hemp-infused, cannabinoid-rich, THC-free craft beer, or a line of such beers, for Faculty Brewing. "Our exciting partnership with Faculty Brewing positions us as one of the first Canadian companies to secure an agreement for research and development, analytical and regulatory services relating to a hemp- and cannabis-infused beverage," said Rob Abenante, President and CEO of Abattis. "By aiming to develop a line of functional beers, each based on a different type of hemp extract, we hope to have a product that is compliant and market-ready as soon as Health Canada releases its new regulatory framework for hemp and cannabis-infused beverages," added Mr. Abenante.

Vitality Biopharma, Inc. (OTCQB: VBIO) is a company focused on the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. Earlier in January announced that it has submitted an orphan drug designation request for VITA-100 to the U.S. Food & Drug Administration (FDA). Upon approval, VITA-100 would be designated as an orphan drug for the treatment of pediatric ulcerative colitis (UC), a form of pediatric inflammatory bowel disease. "In young children, ulcerative colitis can often be hyperactive and difficult to control using existing FDA-approved medications," said Robert Brooke, CEO and Co-Founder of Vitality Biopharma. "Given the mounting clinical data documenting use of cannabinoids for treatment of gastrointestinal disorders, we are very excited about the potential of VITA-100 and our cannabosides platform to provide a meaningful impact for these patients, helping them to stabilize their disease and avoid debilitating surgeries."

Subscribe Now! Watch us report LIVE

Follow us on Twitter for real time Financial News Updates:  

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For global payout, inc. financial news dissemination and PR services, has been compensated four thousand dollars for financial news dissemination and PR services by cambridge consultants. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit:


        For further information: